---
schema_version: "secwatch.filing_event.v1"
accession: "0001714899-24-000076"
form_type: "8-K"
ticker: "DNLI"
cik: "0001714899"
company_name: "Denali Therapeutics Inc."
filed_at: "2024-02-27T23:59:59+00:00"
generated_at: "2026-06-05T12:16:36.062262+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Denali reports Q4 net loss $119.5M, announces ~$500M PIPE and spin-out of preclinical small molecules

## Summary
- Net loss $119.5M in Q4 vs $98.7M YoY; full year net loss $145.2M vs $326.0M on $330.5M collaboration revenue (Biogen ATV:Abeta option $293.9M).
- PIPE financing of ~$500M gross proceeds: 3.24M shares and 26.05M pre-funded warrants at ~$17.07 per unit; cash runway into 2028.
- Plans to spin out preclinical small molecule portfolio to focus on TV-enabled platforms; CD98hc TV platform announced.
- Phase 2/3 COMPASS (MPS II) and HEALEY ALS (DNL343) enrollment expected to complete in 2024.
- SAR443820/DNL788 (RIPK1) missed ALS Phase 2 HIMALAYA primary endpoint; ongoing MS Phase 2 unaffected.

## SEC filing metadata
- accession: 0001714899-24-000076
- form_type: 8-K
- ticker: DNLI
- cik: 0001714899
- company_name: Denali Therapeutics Inc.
- filed_at: 2024-02-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1714899/000171489924000076/0001714899-24-000076-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1714899/000171489924000076/dnli-20240227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001714899-24-000076
- JSON: https://secwatch.observer/filing/0001714899-24-000076.json
- Plain text: https://secwatch.observer/filing/0001714899-24-000076.txt

## Key facts
- Earnings Releases
  Denali Therapeutics Inc. reported financial results for the fourth quarter and year ended December 31, 2023.
  - Period: the fourth quarter and year ended December 31, 2023
  - Result: reported results
  source text: Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases, today reported financial results for the fourth quarter and year ended December 31, 2023, and provided business highlights.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1714899/000171489924000076/0001714899-24-000076-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.